Life Extension Magazine

Life Extension Magazine August 2004

A New, Independent Risk Factor for Heart Disease

By William Faloon

LE Magazine August 2004

A New, Independent Risk Factor for Heart Disease

Millions of Needless Heart Attacks
It is remarkable how ignorant physicians remain about the lifesaving benefits of testosterone replacement therapy. An overwhelming volume of data shows that higher levels of testosterone protect against disorders as diverse as Alzheimer’s dementia, type II diabetes, abdominal obesity, osteoporosis, muscle wasting, depression, cognitive decline, loss of libido, inability to achieve erection, inflammatory-related syndromes, and a range of cardiovascular diseases.

The new data presented in this editorial, along with numerous previous studies, indicate that cardiologists have overlooked the remarkable benefits of testosterone replacement in the treatment of their patients. Of particular interest is the ability of testosterone and other hormone replacement therapies to lower cholesterol levels.27-29 Doctors are prescribing side-effect-prone statin drugs, when for many patients, testosterone enhancement would reduce cholesterol and possibly C-reactive protein.

The failure of doctors to recognize the critical importance of aging men maintaining youthful testosterone levels has resulted in millions of needless heart attacks.

For many years, the Life Extension Foundation has urged members to have their blood tested for free testosterone and other critical hormones. For those who test deficient for these hormones, we have recommended a variety of approaches that would enable hormone levels to be safely restored to a youthful profile. Our current Male (and Female) Hormone Modulation protocols can be found in our Disease Prevention and Treatment reference book, or can be accessed online at our website (www.lef.org).29

For $75 a year, Life Extension members learn what their doctors are not doing to keep them alive. In the case of testosterone replacement for aging men, this need has been obvious for years.

Do not wait for your doctor to discover the incredible value of testosterone replacement therapy. You may not live that long! Please check your blood for free testosterone, PSA, and other hormones such as estradiol, and then follow our protocols to re-establish your levels to those of a healthy 21-year-old. Most people are pleasantly surprised to find how much better they feel when these critical hormones are restored.

For longer life,
image

William Faloon

P.S. If your doctor will not prescribe these hormone blood tests, call 1-800-208-3444 to order them directly.

References

1. Phillips GB, Pinkernell BH, Jing TY. Are major risk factors for myocardial infarction the major predictors of degree of coronary artery disease in men? Metabolism. 2004 Mar;53(3):324-9.

2. Ito MK. Advances in the understanding and management of dyslipidemia: using niacin-based therapies. Am J Health Syst Pharm. 2003 Jul 1;60(13 Suppl 2):S15-21; quiz S25.

3. Mossop RT. Trivalent chromium, in atherosclerosis and diabetes. Cent Afr J Med. 1991 Nov;37(11):369-74.

4. Bahijri SM. Effect of chromium supplemen- tation on glucose tolerance and lipid profile. Saudi Med J. 2000 Jan;21(1):45-50.

5. Bahijiri SM, Mira SA, Mufti AM, Ajabnoor MA. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med J. 2000 Sep;21(9):831-7.

6. Lavy A, Fuhrman B, Markel A, et al. Effect of dietary supplementation of red or white wine on human blood chemistry, hematology and coagulation: favorable effect of red wine on plasma high-density lipoprotein. Ann Nutr Metab. 1994;38(5):287-94.

7. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly. Circulation. 2004 May 4;109(17):2074-9.

8. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004 Apr;90(4):446-7.

9. Svartberg J, Jenssen T, Sundsfjord J, Jorde R. The associations of endogenous testos- terone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromso Study. Diabetes Metab. 2004 Feb;30(1):29-34.

10. Available at: http://www.lef.org/magazine/ mag2004/jan2004_cover_aging_01.htm Accessed May 13, 2004.

11. Available at: http://www.lef.org/ magazine/mag2003/may2003_awsi_01.html. Accessed May13, 2004.

12. Available at: http://www.lef.org/magazine/ mag2003/jan2003_report_ carnosine_01.html. Accessed May 13, 2004.

13. Dobrzycki S, Serwatka W, Nadlewski S, et al. An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. J Med Invest. 2003 Aug;50(3-4):162-9.

14. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J. 2003 May;24(10):909-15.

15. Won E, Won J, Kwon S, LeeY, Nam T, Ahn D. Testosterone causes simultaneous decrease of [Ca2+]I and tension in rabbit coronary arteries: by opening voltage dependent potassium channels. Yonsei Med J. 2003 Dec 30;44(6):1027-33.

16. Callies F, Stromer H, Schwinger RH. Administration of testosterone is associated with a reduced susceptibility to myocardial ischemia, Endocrinology. 2003 Oct;144(10):4478-83.

17. Available at: http://www.lef.org/ protocols/prtcl-130.shtml. Accessed May 13, 2004.

18. Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1410-6

19. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004 Jan 20;108(3):418-24.

20. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003 Dec;170(6 Pt 1):2348-51.

21. Raivio T, Santti H, Schatzl G, et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate. 2003 May 15;55(3):194-8.

22. Higher serum free testosterone is associated with an increased risk of prostate cancer. J Urol. 2004 May 9;171(4).

23. Available at: http://www.cancer.org/down loads/STT/CAFF_finalPWSecured.pdf. Accessed May 17, 2004.

24. Available at: http://www.cancer.org/ docroot/CRI/content/CRI_2_4_2X_ What_are_the_risk_factors_for_prostate _cancer_36.asp?sitearea. Accessed May 17, 2004.

25. Available at: http://www.health.uab.edu/ show.asp?durki=15963. Accessed May 18, 2004.

26. Available at: http://www.lef.org/protocols/ prtcls-txt/t-prtcl-130.html. Accessed May 17, 2004.

27. Dzugan SA, Smith RA. Hypercholesterolemia treatment: a new hypothesis or just an accident? Med Hypothesis. 2002 Dec;59(6):751-6.

28. Dzugan SA, Smith RA. Broad spectrum restoration in natural steroid hormones as possible treatment for hypercholesterolemia. Bull Urg Rec Med. 2002;3(2):278- 84.

29. Available at: http://www.lef.org/protocols/prtcls-txt/t-prtcl-130.html. Accessed May 17, 2004.